Customer Concentration (Tables)

12 Months Ended

Dec. 31, 2020

Risks and Uncertainties [Abstract]

Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:

	Eight Months Ended August 31,		Year Ended December 31,
(in thousands)	2020 (1)		2019 (1)		2018 (1)
Biogen	—	%	—	%	14	%
LENSAR	99	%	100	%	77	%

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

Total revenues by geographic area are based on the country of domicile of the counterparty to the agreement are as follows:

	Eight Months Ended August 31,		Year Ended December 31,
(in thousands)	2020		2019		2018
United States	$	6,656	$	15,151	$	21,434
Europe	2,078		3,438		2,451
Rest of world	4,337		12,117		8,143
Total revenues (1)	$	13,071	$	30,706	$	32,028

________________

(1) The amounts above exclude product sales in our Pharmaceutical segment and royalty rights held for sale in the Income Generating Assets segment, each of which is included in the Statements of Operations as Loss from discontinued operations. See Note 4, Discontinued Operations Classified as Assets Held for Sale, for additional information.

One customer accounted for more than 10% of accounts receivable, net as of December 31, 2019.